eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Review paper

Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review

Hio Fong Leong
1
,
Wen-hui Wang
1
,
Fen Peng
1

  1. Department of Dermatology, Peking University Third Hospital, Beijing, China
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2024.141128
Online publish date: 2024/07/02
Article files
- Biologics.pdf  [0.16 MB]
- Supplementary Biologics.pdf  [0.18 MB]
Get citation
 
 
1. Mrowietz U, van de Kerkhof PC. Management of palmoplantar pustulosis: do we need to change? Br J Dermatol 2011; 164: 942-6.
2. Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-1 cytokine family--balance between agonists and antagonists in inflammatory diseases. Cytokine 2015; 76: 25-37.
3. Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol 2016; 17: 906-13.
4. Renne J, Schäfer V, Werfel T, Wittmann M. Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation. Br J Dermatol 2010; 162: 1198-205.
5. Cai Y, Xue F, Quan C, et al. A critical role of the IL-1β-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis. J Investig Dermatol 2019; 139: 146-56.
6. Naik HB, Pichard DC, Schwartz DM, et al. Anakinra for refractory pustular psoriasis: a phase II, open-label, dose-escalation trial. J Am Acad Dermatol 2022; 87: 1380-3.
7. Cro S, Cornelius VR, Pink AE, et al.; APRICOT Study Group. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT). Br J Dermatol 2021; 186: 245-56.
8. Wendling D, Prati C, Aubin F. Anakinra treatment of SAPHO syndrome: short-term results of an open study. Ann Rheum Dis 2012; 71: 1098-100.
9. Hüffmeier U, Wätzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014; 170: 202-4.
10. Hüffmeier U, Wätzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2014; 170: 202-4.
11. Viguier M, Guigue P, Pagès C, et al. Successful treatment of generalized pustular psoriasis with the interleukin-1-receptor antagonist Anakinra: lack of correlation with IL1RN mutations. Ann Inter Med 2010; 153: 66-7.
12. Mansouri B, Kivelevitch D, Campa M, Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab. Clin Exp Dermatol 2016; 41: 324-6.
13. Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008; 181: 669-79.
14. Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20: 845-7.
15. Anttila HS, Reitamo S, Erkko P, et al. Interleukin-8 immunoreactivity in the skin of healthy subjects and patients with palmoplantar pustulosis and psoriasis. J Investig Dermatol 1992; 98: 96-101.
16. Skov L, Beurskens FJ, Zachariae CO, et al. IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 2008; 181: 669-79.
17. Balato A, Scala E, Balato N, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther 2017; 17: 1363-74.
18. Miossec P, Kolls JK. Targeting IL-17 and Th17 cells in chronic inflammation. Nature reviews. Drug Discov 2012; 11: 763-76.
19. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol 2015; 73: 400-9.
20. Langley RG, Sofen H, Dei-Cas I, et al. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol 2023; 188: 198-207.
21. Bodemer C, Kaszuba A, Kingo K, et al. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol 2021; 35: 938-47.
22. Iversen L, Conrad C, Eidsmo L, et al. Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: week 52 results from the STEPIn study. J Eur Acad Dermatol Venereol 2023; 37: 1004-16.
23. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol 2018; 32: 1507-14.
24. Magnolo N, Kingo K, Laquer V, et al. Efficacy of secukinumab across subgroups and overall safety in pediatric patients with moderate to severe plaque psoriasis: week 52 results from a phase III randomized study. Paediatr Drugs 2022; 24: 377-87.
25. Puig L, Augustin M, Blauvelt A, et al. Effect of secukinumab on quality of life and psoriasis-related symptoms: a comparative analysis versus ustekinumab from the CLEAR 52-week study. J Am Acad Dermatol 2018; 78: 741-8.
26. Bissonnette R, Luger T, Thaçi D, et al. Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. Br J Dermatol 2017; 177: 1033-42.
27. Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar(PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol 2014; 28: 1298-305.
28. Lai Y, Li D, Li C, et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity 2012; 37: 74-84.
29. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-102.
30. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9.
31. Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol 2019; 80: 1344-52.
32. Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol 2017; 76: 70-80.
33. Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol 2016; 43: 1011-7.
34. Griffiths CE, Reich K, Lebwohl M, et al.; UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386: 541-51.
35. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
36. Puig L, Lebwohl M, Bachelez H, et al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol 2020; 82: 352-9.
37. Gordon KB, Kimball AB, Chau D, et al. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol 2014; 170: 705-15.
38. Gottlieb AB, Gordon K, Hsu S, et al. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials. J Eur Acad Dermatol Venereol 2018; 32: 1305-13.
39. Nakagawa H, Niiro H, Ootaki K; Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci 2016; 81: 44-52.
40. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014; 370: 2295-306.
41. Mease PJ, Helliwell PS, Hjuler KF, et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis 2021; 80: 185-93.
42. Papp KA, Reid C, Foley P, et al. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Investig Dermatol 2012; 132: 2466-9.
43. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Investig Dermatol 2013; 133: 17-26.
44. Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol 2011; 20: 845-7.
45. Pinter A, Wilsmann-Theis D, Peitsch WK, Mössner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol 2019; 46: 426-30.
46. Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med 2015; 21: 719-29.
47. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125-30.
48. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-87.
49. Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Investig Dermatol 2009; 129: 1339-50.
50. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010; 63: 457-65.
51. Gerdes S, Franke J, Domm S, Mrowiet, U. Ustekinumab in the treatment of palmoplantar pustulosis. Br J Dermatol 2010; 163: 1116-8.
52. Hegazy S, Konstantinou MP, Bulai Livideanu C, et al. Efficacy of ustekinumab in palmoplantar pustulosis. J Eur Acad Dermatol Venereol 2018; 32: e204e206.
53. Bertelsen T, Kragballe K, Johansen C, Iversen L. Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. Int J Dermatol 2014; 53: e464-6. 1
54. Husson B, Barbe C, Hegazy S, et al.; « Groupe de Recherche sur le Psoriasis » de la Société Française de Dermatologie. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol 2020; 34: 2330-8.
55. Au SC, Goldminz AM, Kim N, et al. Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis. J Dermatol Treat 2013; 24: 179-87.
56. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti-interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial. JAMA Dermatol 2018; 154: 309-16.
57. Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol 2019; 155: 1153-61.
58. Mease PJ, Rahman P, Gottlieb AB, et al.; DISCOVER-2 Study Group. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 2020; 395: 1126-36.
59. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650-61.
60. Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet 2019; 394: 576-86.
61. Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol 2020; 156: 649-58.
62. Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol 2023; 189: 540-52.
63. Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol 2023; 89: 1149-58.
64. Gooderham M, Pinter A, Ferris LK, et al. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol 2022; 36: 855-65.
65. Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol 2019; 180: 1348-51.
66. Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2/3 trial. J Dermatol 2019; 46; 686-94.
67. Caldarola G, Zangrilli A, Palmisano G, et al. Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience. Drugs Context 2023; 12: 2023-1-8.
68. Del Campo DC. Successful use of tildrakizumab for treatment of palmoplantar pustulosis: a case report. J Drugs Dermatol 2021; 20: 1117-9.
69. Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 2017; 390: 276-88.
70. Goldminz AM, Au SC, Kim N, et al. NF-kB: an essential transcription factor in psoriasis. J Dermatol Sci 2013; 69: 89-94.
71. Deng Y, Chang C, Lu Q. The inflammatory response in psoriasis: a comprehensive review. Clin Rev Allergy Immunol 2016; 50: 377-89.
72. Gottlieb AB, Chaudhari U, Mulcahy LD, et al. Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003; 48: 829-35.
73. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842-7.
74. Antoni C, Krueger GG, de Vlam K, et al.; IMPACT 2 Trial Investigators. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64: 1150-7.
75. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51: 534-42.
76. Reich K, Nestle FO, Wu Y, et al. Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Eur J Dermatol 2007; 17: 381-6.
77. Yang HZ, Wang K, Jin HZ, et al. Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial. Chinese Med J 2012; 125: 1845-51.
78. Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-9.
79. Torii H, Nakagawa H; Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 9: 40-9.
80. Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2011; 25: 1402-8.
81. Kromer C, Wilsmann-Theis D, Gerdes S, et al. Drug survival and reasons for drug discontinuation in palmoplantar pustulosis: a retrospective multicenter study. J Dtsch Dermatol Ges 2019; 17: 503-16.
82. Sladden MJ, Clarke PJ, Wettenhall J. Infliximab-induced palmoplantar pustulosis in a patient with Crohn disease. Arch Dermatol 2007; 143: 1449.
83. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutrition 2011; 52: 230-2.
84. Cemil BC, Atas H, Canpolat F, et al. Infliximab-induced discoid lupus erythematosus. Lupus 2013; 22: 515-8.
85. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
86. McInnes IB, Behrens F, Mease PJ, et al.; EXCEED Study Group. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 2020; 395: 1496-505.
87. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
88. Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010; 63: 448-56.
89. Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 40-9.
90. Cai L, Gu J, Zheng J, et al. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol 2017; 31: 89-95.
91. Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66: 241-51.
92. Yawalkar N, Hunger RE. Successful treatment of recalcitrant palmoplantar pustular psoriasis with sequential use of infliximab and adalimumab. Dermatology 2009; 218: 79-83.
93. Yang Q, Xiang T, Wu Y, et al. SAPHO syndrome with palmoplantar pustulosis as the first manifestation successfully treated with adalimumab. Clin Cosmet Investig Dermatol 2022; 15: 2547-54.
94. Ibis N, Hocaoglu S, Cebicci MA, et al. Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review. Immunotherapy 2015; 7: 717-20.
95. Gkalpakiotis S, Fridman M, Tivadar S. Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab. Dermatol Ther 2022; 12: 605-9.
96. Weinberg JM, Ritu Saini BA. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis 2003; 71: 25-9.
97. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003; 139: 1627-32.
98. Kasche A, Pfab F, Hein R, et al. Severe psoriasis pustulosa palmaris et plantaris (Barber-Königsbeck) treated successfully with soluble tumour necrosis factor receptor fusion protein (etanercept). J Eur Acad Dermatol Venereol 2007; 21: 255-7.
99. Antoniou C, Nicolaidou E, Moustou AE, et al. Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin. J Eur Acad Dermatol Venereol 2009; 23: 854-5.
100. Bissonnette R, Poulin Y, Bolduc C, et al. Etanercept in the treatment of palmoplantar pustulosis. J Drugs Dermatol 2008; 7: 940-6.
101. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 2005; 153: 1243-4.
102. Seol JE, Park IH, Lee W, et al. Palmoplantar pustulosis induced by both adalimumab and golimumab for treatment of ankylosing spondylitis. Ann Dermatol 2016; 28: 522-3.
103. Wendling D, Prati C. Paradoxical effects of anti-TNF-a agents in inflammatory diseases. Exp Rev Clin Immunol 2014; 10: 159-69.
104. Elias M, Zhao S, Le HT, et al. IL-36 in chronic inflammation and fibrosis – bridging the gap? J Clin Investig 2021; 131: e144336.
105. Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Investig Dermatol 2011; 131: 2428-37.
106. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8: 950-7.
107. Pène J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol; 180: 7423-30.
108. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis 2014; 73: 1689-94.
109. Ganesan R, Raymond EL, Mennerich D, et al. Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. mAbs 2017; 9: 1143-54.
110. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are the dominant cytokines in Palmar Plantar Pustulosis. J Dermatol Sci 2016; 84: E99.
111. Bachelez H, Choon SE, Marrakchi S, et al.; Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med 2021; 85: 2431-40.
112. Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet 2023; 402: 1541-51.
113. Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther 2021; 11: 571-85.
114. Burden AD, Bissonnette R, Navarini AA, et al. Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase iib, dose-finding study. Dermatol Ther 2023; 13: 2279-97.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.